New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 2, 2023--

Related Keywords

United States ,American ,Semin Nephrol ,Christian Rommel ,American Kidney Fund ,National Diabetes Statistics ,Head Of Research ,National Institute Of Diabetes ,Facebook ,American Diabetes Association ,Bayer Healthcare Pharmaceuticals Inc ,Twitter ,National Institutes Of Health ,Clinical Trials Program ,American Society Of Nephrology ,American Association Of Clinical Endocrinology ,Centers For Disease ,American Society ,Kidney Week ,Executive Committee ,Kerendia Phase ,American Association ,Clinical Endocrinology ,Kidney Disease ,Improving Global Outcomes ,Prescribing Informationfor ,Trials Program ,Chronic Kidney Disease Associated ,Bayer Healthcare Pharmaceuticals ,Rev Dis ,Diabetes Statistics Report ,Its Burden ,Disease Control ,Accessed July ,Accessed May ,States Renal Data ,National Institutes ,National Institute ,Kidney Diseases ,Media Contact ,Business Wire ,Region ,